KDR and neoplasm: Anlotinib, as a novel oral multitargeting receptor tyrosine kinase inhibitor (TKI), mainly targets the intracellular ATP-binding site of VEGFRs (especially VEGFR2), FGFR1-4, PDGFR α/β, c-Kit, and Ret, preventing their phosphorylation and the subsequent activation of downstream signaling pathways to inhibit tumor angiogenesis and disease progression15.